Synthetic mRNA is indeed the highway for today’s therapeutics, whether you’re working on developing new drugs against cancer targets, or whether you aim to develop new vaccines, Covid-19 being one of them. So, how can you obtain your mRNA within just a few weeks, ready to explore these potential applications? Read on to see how we can help you achieve this.

As detailed in a separate post, bit.bio have developed a novel cellular reprogramming technology, opti-ox™¹ (optimized inducible overexpression), that can generate functional cells with high consistency from human induced pluripotent stem cells (iPSCs). opti-ox overcomes gene silencing and enables controlled expression of transcription factors, and as a result, deterministic induction of a new cell identity. The resulting mature cells are physiologically relevant and phenotypically characterised, and for the first time, available at scale, offering predictive, in vitro, cells for research and drug screening.

Here we’ll be taking a closer look at the products already available for researchers. As the technology can be applied to generate many other mature cell types, more will be coming soon, including CNS cells, immune cells, and cells for toxicology and disease modelling.

The first human iPSC-derived products developed using opti-ox are the ioGlutamatergic Neurons and ioSkeletal Myocytes, which are both available across Europe through tebu-bio. There will be more to follow…

To overcome current cell model limitations, bit.bio have developed a new, innovative technology to reprogram human stem cells with precise control of transcription factor expression through iPSC engineering.

You can already access human cells developed using this new technology through tebu-bio in Europe!  But first, let’s take a look at the technology in detail. If you like, you can also discover the available products here.

Every type of cell has different membrane properties, meaning that transfection of your specific nucleic acid can become challenging.

To overcome transfection limitations, RJH Biosciences have developed a new range of transfection reagents to transfect mammalian cells with specific nucleic acids.

Access to this new technology now through tebu-bio in Europe!